Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
15.5 GBX | 0.00% | +26.53% | -32.61% |
Apr. 02 | Belluscura sees financial hit from delay to closing TMT acquisition | AN |
Apr. 02 | AIM WINNERS & LOSERS: 88 Energy finds oil at Hickory-1; Redx to delist | AN |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- One of the major weak points of the company is its financial situation.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
Ratings chart - Surperformance
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-32.61% | 32.53M | - | ||
-6.46% | 179B | C+ | ||
+3.39% | 113B | C | ||
-3.68% | 67.88B | A | ||
+5.44% | 52.03B | B- | ||
+5.70% | 43.3B | B- | ||
+4.03% | 41.79B | B+ | ||
+25.42% | 32.49B | B | ||
+14.00% | 25.65B | A- | ||
-4.29% | 24.55B | A- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- BELL Stock
- Ratings Belluscura plc